Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab

Authors: Lorena Incorvaia, Sarah Scagliarini, Fernando Sabino Marques Monteiro, Hideki Takeshita, Jose Carlos Tapia, María Natalia Gandur Quiroga, Elaine Lam, Deniz Tural, Lazar Popovic, Saul Campos-Gomez, Paolo Andrea Zucali, Augusto Mota, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Ondřej Fiala, Nuno Vau, Patrizia Giannatempo, Halima Abahssain, Andrea Benedetto Galosi, Giuseppe Badalamenti, Jindrich Kopecky, Aristotelis Bamias, Johannes Landmesser, Jawaher Ansari, Fabio Calabrò, Francesco Massari, Sebastiano Buti, Joaquim Bellmunt, Matteo Santoni

Source: Scientific Reports, Vol 15, Iss 1, Pp 1-9 (2025)

Subject Terms: Immunotherapy, NCT05290038, Pembrolizumab, Sex differences, Urothelial Cancer, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/56d24ec802e447bd9c9995e0b420ddf4

Sex-specific differences in recurrence and progression following cytostatic intravesical chemotherapy for non-muscle invasive urothelial bladder cancer (NMIBC)

Authors: Laila Schneidewind, Bernhard Kiss, Thomas Neumann, Jennifer Kranz, Friedemann Zengerling, Sebastian Graf, Annabel Graser, Annemarie Uhlig

Source: Journal of Cancer Research and Clinical Oncology, Vol 151, Iss 2, Pp 1-12 (2025)

Subject Terms: Bladder cancer, Urothelial cancer, MIBC, Intravesical chemotherapy, Gender, Sex, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1432-1335

Access URL: https://doaj.org/article/ae83a650c8324f46bb05982c2d5664dc

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial

Authors: Junya Furukawa, Yasumasa Kakei, Sae Murakami, Hiroshi Kita, Hideto Ueki, Takuto Hara, Jun Teishima, Nobuyuki Hinata, Hideaki Miyake, Masato Fujisawa, Toshiro Shirakawa

Source: BMC Cancer, Vol 25, Iss 1, Pp 1-11 (2025)

Subject Terms: B440, WT-1 protein, Clinical trial, advanced urothelial cancer, ICI, Phase 1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/ab41698fc7d04d73bef3e15a6a1ff7e5

The role of immunohistochemical analysis in determining the molecular subtypes of bladder cancer

Authors: M. V. Berkut, A. S. Artemyeva, A. V. Khokhlova, A. I. Saad, A. K. Nosov

Source: Успехи молекулярной онкологии, Vol 11, Iss 4, Pp 102-113 (2024)

Subject Terms: bladder cancer, urothelial cancer molecular subtype, bladder cancer treatment, immunohistochemical examination, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://umo.abvpress.ru/jour/article/view/733; https://doaj.org/toc/2313-805X; https://doaj.org/toc/2413-3787

Access URL: https://doaj.org/article/d37e851d707c4df39c77a129a99ee4ce

Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer

Authors: Renate Pichler, Josef Fritz, Sarah Maier, Melanie R. Hassler, Johanna Krauter, David D`Andrea, Ekaterina Laukhtina, Kilian Gust, Keiichiro Mori, Karl H. Tully, Dora Niedersuess-Beke, Lea Korber, Jasmin Alija Spiegelberg, Thomas Bauernhofer, José D. Subiela, Roman Mayr, Andreas Kronbichler, Marco Moschini, Jeremy Teoh, Benjamin Pradere, Shahrokh F. Shariat, Hanno Ulmer, Laura S. Mertens, European Association of Urology–Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group

Source: Cancer Immunology, Immunotherapy, Vol 74, Iss 1, Pp 1-10 (2024)

Subject Terms: Urothelial cancer, Metastatic, Immunotherapy, Immune checkpoint inhibitors, Adverse events, Target trial emulation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1432-0851

Access URL: https://doaj.org/article/dabe3b175be24efc9e75632af91127fd

Impact of immigration background on feasibility of electronic patient-reported outcomes in advanced urothelial cancer patients

Authors: Ozan Yurdakul, Abdulkarim Alan, Johanna Krauter, Stephan Korn, Kilian Gust, Shahrokh F. Shariat, Melanie R. Hassler

Source: Health and Quality of Life Outcomes, Vol 22, Iss 1, Pp 1-9 (2024)

Subject Terms: Electronic patient-reported outcomes, urothelial cancer, feasibility study, immigration background, Computer applications to medicine. Medical informatics, R858-859.7

File Description: electronic resource

Relation: https://doaj.org/toc/1477-7525

Access URL: https://doaj.org/article/37b1e31cfc1743cdb9959c398deede05

Use of inpatient systemic chemotherapy and/or radiotherapy and related predictive factors, healthcare resource utilization, and direct hospitalization costs for metastatic urothelial cancer: findings from a real-world retrospective observational study derived from the national hospital discharge claims database in Italy

Authors: Mairead Kearney, Melissa Kirker, Allison Thompson, Norbek Gharibian, Martina Furegato, Cécile Pacheco, Seham Issa, Reyhan Hasanova, Paolo Sciattella, Matteo Scortichini, Francesco Saverio Mennini

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-20 (2024)

Subject Terms: Urothelial cancer, Metastatic, Treatment rate, Predictive factors, HCRU, Costs, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/7d7f898f051341ce94b0f0264277f20a

A new technique for ureteral resection to prevent urine dissemination and cancer seeding

Authors: Hayato Hoshina, Toru Sugihara, Masayuki Kurokawa, Kaori Endo, Ei‐ichiro Takaoka, Satoshi Ando, Haruki Kume, Tetsuya Fujimura

Source: IJU Case Reports, Vol 7, Iss 6, Pp 454-458 (2024)

Subject Terms: laparoscopic radical nephroureterectomy (LNU), recurrence, robot‐assisted radical ureterectomy (RAU), transurethral resection of the bladder tumor (TURBT), upper tract urothelial cancer (UTUC), Diseases of the genitourinary system. Urology, RC870-923

File Description: electronic resource

Relation: https://doaj.org/toc/2577-171X

Access URL: https://doaj.org/article/80fcecdab6a14bf9a9955532a13a0cf0

Assessing expression patterns of PTGR1, a potential biomarker for acylfulven sensitivity in urothelial carcinoma

Authors: Dag Rune Stormoen, Signe Lehn, Kent W. Mouw, Zoltan Szallasi, Linea Cecilie Melchior, Line Hammer Dohn, Judit Börcsok, Maria Rossing, Birgitte Grønkaer Toft, Helle Pappot

Source: Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)

Subject Terms: Bladder cancer, Urothelial cancer, Biomarker, Validation study, DNA repair deficiency, PTGR1, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/cbe03a455d9d4cd08c3d82aaa8d9d930

Central pathology review and its prognostic value in upper tract urothelial carcinoma patients: a nationwide multi-institutional study

Authors: Yung-Tai Chen, Hsiang Ying Lee, Wen-Jeng Wu, Ching-Chia Li, Chih-Hung Lin, Chung-Tai Yue, Yuan-Hong Jiang, Yu-Khun Lee, Kuan Hsun Huang, Yao-Chou Tsai

Source: Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)

Subject Terms: Upper tract urothelial cancer, Urothelial cancer, Pathology review, Radical nephroureterectomy, Multi-collinearity, Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/48208513c951401193444fcac52fab91

Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: an observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)

Authors: Francesca Zacchi, Anna Sordo, Irene Torresan, Clara Lorenzi, Ester Tasselli, Sarah Pafumi, Silvia Palmerio, Emilia Durante, Nicola Inzerilli, Mattia Pellicciari, Davide Pastorelli, Michele Milella, Giulia Lorenzoni, Sara Merler, Andrea Zivi

Source: Frontiers in Oncology, Vol 15 (2025)

Subject Terms: urothelial cancer, immunotherapy, avelumab, pembrolizumab, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2025.1532421/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/18e643b89a5a48fea3a42914cb27269d

Icaritin inhibits the progression of urothelial cancer by suppressing PADI2-mediated neutrophil infiltration and neutrophil extracellular trap formation

Authors: Zezhong Mou, Yiling Chen, Jinzhong Hu, Yun Hu, Lujia Zou, Xinan Chen, Shenghua Liu, Qiuping Yin, Jian Gong, Shuchen Li, Shanhua Mao, Chenyang Xu, Haowen Jiang

Source: Acta Pharmaceutica Sinica B, Vol 14, Iss 9, Pp 3916-3930 (2024)

Subject Terms: Icaritin, Neutrophil, Neutrophil extracellular trap, PADI2, Urothelial cancer, Therapeutics. Pharmacology, RM1-950

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2211383524002600; https://doaj.org/toc/2211-3835

Access URL: https://doaj.org/article/8171b419e6c14c90997b7f0b643393ca

Prolonged Response to Osimertinib in EGFR-Mutated Metastatic Urothelial Carcinoma, a Case Report

Authors: Sareen T. Ali, David J. VanderWeele

Source: Current Oncology, Vol 31, Iss 7, Pp 4015-4021 (2024)

Subject Terms: urothelial cancer, bladder cancer, EGFR, TKI, osimertinib, case report, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/31/7/298; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/48ce2d3b52a94770baf63023f1f06161

Treatment Patterns and Real-World Outcomes for Locally Advanced or Metastatic Urothelial Cancer in the Era of Immunotherapy

Authors: Hassler, Melanie R. ^a, Moedlagl, Verena ^a, Hindinger, Hanna ^a, Krauter, Johanna ^a, Klager, Sonja ^a, Resch, Irene ^a, Huebner, Nicolai ^a, Yurdakul, Ozan ^a, Ofner, Heidemarie ^a, Korn, Stephan M. ^a, D'Andrea, David ^a, Gust, Kilian ^a, Shariat, Shahrokh F. ^{a, b, c, d, e, f, g, ⁎}

Source: In European Urology Focus September 2024 10(5):779-787

Advances in the Treatment of Kidney and Upper Urinary Tract Cancers

Contributors: Zapała, Łukasz, Rajwa, Pawel

Subject Terms: renal cell carcinoma, risk models, survival analysis, charlson comorbidity index, systemic inflammatory markers, upper tract urothelial carcinoma, UTUC, sPD-L1, soluble programmed death ligand-1, biomarker, prognosis, immune checkpoint inhibitor therapy, chemotherapy, radical nephroureterectomy, focal therapy, kidney cancer, thermal ablation, renal carcinoma, RCC, PD-1, PD-L1, nivolumab, kidney tumor, systemic inflammatory response syndrome, nephrectomy, globotriaosylceramide, rhamnose-binding lectin, sunitinib, brain metastases, neurosurgery, targeted therapy, basement membrane, diagnostic, renal cancer, lncRNA, prognostic model, immunotherapy, prostate cancer, transplant, immunosuppression, progression, metastatic prostate cancer, upper tract urothelial cancer, Balkan endemic nephropathy, morphology, CKs, CD44, tyrosine kinase inhibitors (TKI), cabozantinib, metastatic renal cell carcinoma (mRCC), adverse events, predictive factor, Applied mathematics

File Description: application/octet-stream

Access URL: https://directory.doabooks.org/handle/20.500.12854/137710
https://mdpi.com/books/pdfview/book/8935

Evolving treatment patterns and outcomes among patients with metastatic urothelial carcinoma post-avelumab maintenance approval: insights from The US Oncology Network

Authors: Li, H. ^{1, ∗}, Sura, S. ², Babcock, A. ¹, Herms, L. ², Guo, J. ², Conkling, P. ², Franco, S. ¹, Singhal, P. ¹, Mamtani, R. ³, Bupathi, M. ⁴

Source: In ESMO Real World Data and Digital Oncology March 2025 7

A French Multicenter Real-Life Study on the Biological and Clinical Parameters Associated With Response to Immune Checkpoint Inhibitors (ICIs) in Second-Line Treatment of Advanced Urothelial Carcinoma: Impact of Antibiotics Administration at the Time of ICIs Initiation

Authors: Grassi, Pierre ^{1, ⁎}, Hilgers, Werner ², Boissier, Romain ³, Bertucci, Alexandre ¹, Bruyat, Damien ¹, Duffaud, Florence ¹, Enoch, Faustine ¹, Rochigneux, Philippe ^{4, 5}, Mancini, Julien ⁶, Deville, Jean-Laurent ¹

Source: In Clinical Genitourinary Cancer February 2025 23(1)

FGFR Inhibition in Urothelial Carcinoma

Authors: Li, Roger ^{a, b, ⁎}, Linscott, Joshua ^a, Catto, James W.F. ^c, Daneshmand, Siamak ^d, Faltas, Bishoy M. ^e, Kamat, Ashish M. ^f, Meeks, Joshua J. ^g, Necchi, Andrea ^{h, i}, Pradere, Benjamin ^j, Ross, Jeffrey S. ^{k, l}, van der Heijden, Michiel S. ^m, van Rhijn, Bas W.G. ⁿ, Loriot, Yohann ^o

Source: In European Urology February 2025 87(2):110-122

The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression

Authors: Saal, Jonas ^{a, b, c, ⁎, 1}, Eckstein, Markus ^{d, e, f, 2}, Ritter, Manuel ^{c, g}, Brossart, Peter ^{a, c}, Hölzel, Michael ^{b, c, 3}, Grünwald, Viktor ^{h, i}, Klümper, Niklas ^{b, c, g, 4}

Source: In European Journal of Cancer 17 January 2025 215

Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease

Alternate Title: Implicaciones biológicas y terapéuticas de las alteraciones del receptor del factor de crecimiento de fibroblastos (FGFR) en el cáncer urotelial: una revisión sistemática desde la enfermedad no musculoinvasiva a la metastásica (Spanish; Castilian)

Authors: Pichler, R. ^{a, ⁎, 1}, van Creij, N.C.H. ^{a, 1}, Subiela, J.D. ^{b, 1}, Cimadamore, A. ^c, Caño-Velasco, J. ^d, Tully, K.H. ^e, Mori, K. ^f, Contieri, R. ^{g, h}, Afferi, L. ⁱ, Mari, A. ^j, Soria, F. ^k, Del Giudice, F. ^l, D’Elia, C. ^m, Mayr, R. ⁿ, Mertens, L.S. ^g, Pyrgidis, N. ^o, Moschini, M. ^p, Gallioli, A. ⁱ

Source: In Actas Urológicas Españolas (English Edition) July 2024